Industry news that matters to you.  Learn more

Archives for December 2011

OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response

OvaGene Oncology Inc., a molecular diagnostics company specializing in the development and commercialization of personalized gene-based diagnostics for gynecologic cancer, recently announced that it has completed a major Licensing and Collaboration Agreement with The Moffitt Cancer Center, the only National Cancer Institute (NCI) Comprehensive Cancer Center in Florida. The agreement provides OvaGene with exclusive worldwide rights to develop and commercialize proprietary microRNA-based assays that predict drug response for currently used cancer treating drugs. The proprietary assays were developed and validated at the Moffitt Cancer Center under the leadership of Dr. Johnathan Lancaster, a world renowned scientist and clinician specializing in Women’s Cancers.

Novel In-Vitro Assays Developed for Mandatory EU-wide Allergen Testing

Proteome Sciences recently announced that it has developed a number of novel in-vitro tests for chemical compounds and substances that induce allergies when they come into contact with the skin or the respiratory system. Testing for these allergens in products including chemicals, pharmaceuticals, cosmetics and detergents will become mandatory under EU legislation.

Amarantus Biosciences and Banyan Biomarkers Announce Traumatic Brain Injury Research Collaboration

Amarantus BioSciences, Inc., a biotechnology company developing MANF, a first-in-class disease–modifying therapeutic protein and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect traumatic brain injury (TBI), today announced a collaboration agreement to evaluate MANF’s potential as a disease-modifying agent for the treatment of TBI.